CTXR Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
1.5M
-10.4%
1.7M
-57.7%
3.9M
0
0
Cost of Revenue
491.8K
+49.6%
328.9K
-58.3%
789.2K
0
0
Gross Profit
1.0M
-25.1%
1.3M
-57.6%
3.2M
0
0
Operating Expenses
12.7M
-62.0%
33.5M
+175.4%
12.2M
+44.3%
8.4M
-4.0%
8.8M
R&D
1.1M
-68.6%
3.4M
+109.7%
1.6M
-2.6%
1.6M
+1.2%
1.6M
SG&A
10.0M
-62.3%
26.4M
+163.9%
10.0M
+347.5%
-4040568
-156.4%
7.2M
Operating Income
-11732074
+63.6%
-32194786
-257.0%
-9019208
-6.9%
-8437309
+4.0%
-8788007
EBITDA
-11732074
+63.6%
-32194786
-257.0%
-9019208
-6.9%
-8437309
+4.0%
-8788007
Net Income
-11919260
+57.6%
-28109746
-199.2%
-9393889
-7.4%
-8743646
+5.0%
-9203872
EPS (Basic)
$-0.34
+64.2%
$-0.95
-150.0%
$-0.38
+17.4%
$-0.46
+42.5%
$-0.80
EPS (Diluted)
$-0.34
+64.2%
$-0.95
-150.0%
$-0.38
+17.4%
$-0.46
+42.5%
$-0.80
Shares (Diluted)
26.2M
+17.0%
22.4M
+4.1%
21.5M
+25.1%
17.2M
+56.1%
11.0M
Citius Pharmaceuticals Inc. Common (CTXR) — Financials